Izumi Yasumori, Komori Atsumasa, Yasunaga Yuki, Hashimoto Satoru, Miyashita Taiichiro, Abiru Seigo, Yatsuhashi Hiroshi, Ishibashi Hiromi, Migita Kiyoshi
Department of Rheumatology, NHO Nagasaki Medical Center, Japan.
Intern Med. 2011;50(9):1065-8. doi: 10.2169/internalmedicine.50.4790. Epub 2011 May 1.
We report a 48-year-old man who developed rheumatoid arthritis (RA) after a successful treatment with peg-IFN-alpha plus ribavirin for chronic hepatitis C virus (HCV) infection. He had a history of smoking and a single copy of the HLA-DRB1 shared epitope (SE). In a retrospective analysis, he exhibited the anti-CCP antibodies before the start of IFN plus ribavirin treatment. However, the titers of anti-CCP antibodies and BAFF levels were elevated by the IFN plus ribavirin therapy. These observations suggest that IFN plus ribavirin therapy may work as a "trigger" for RA in genetically and environmentally predisposed individuals by affecting the cytokine network.
